Stock data
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX) reported revenue of US$2.38B and net income of US$770.95M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$2.38B | — | US$1.56B | US$770.95M | — |
| 2024 | US$2.26B | — | US$1.29B | US$858.98M | — |
| 2023 | US$2.35B | — | US$1.49B | US$1.13B | — |
| 2022 | US$2.24B | — | US$307.06M | US$42.83M | — |
| 2021 | US$2.29B | — | US$1.43B | US$619.73M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$674.14M | US$17.88M | — |
| 2026-03-31 | US$630.58M | US$294.69M | — |
| 2025-12-31 | US$621.99M | US$211.21M | — |
| 2025-09-30 | US$609.29M | US$288.22M | — |
| 2025-06-30 | US$578.66M | US$32.18M | — |
| 2025-03-31 | US$568.25M | US$239.35M | — |
| 2024-12-31 | US$593.64M | US$208.21M | — |
| 2024-09-30 | US$564.69M | US$543.99M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.